Ginkgo Results Presentation Deck

Q2 2022 Financial Summary (Unaudited) In millions of USD except new programs and % YoY New programs launched Revenue: Foundry Biosecurity Total revenue Biosecurity cost of sales Research and development (excl. SBC) General and administrative (excl. SBC) Total operating expenses (excl. SBC) (1) Stock-based compensation Loss from operations Net loss Adjusted EBITDA Capital expenditures Three Months Ended June 30, 2022 13 $44 100 145 64 72 48 184 607 (647) (671) (23) 10 2021 7 $22 22 44 17 52 20 89 15 (60) (54) (38) 24 % YOY 86% 105% 355% 231% 274% 38% 143% 107% NM NM NM 38% (60%) (1) For the three months and six months ended June 30, 2022, amounts include $0.8M and $7.0M respectively of employer payroll taxes related to stock-based compensation Six Months Ended June 30, 2022 24 $ 66 247 313 149 128 91 368 1,266 (1,321) (1,263) (23) 13 2021 11 $44 44 88 41 112 38 190 15 (117) (129) (89) 46 % YoY 118% 49% 467% 257% 266% 15% 140% 94% NM NM NM 74% (71%) 12 Property of Ginkgo Bioworks Q2 2022 UPDATE & BUSINESS REVIEW

View entire presentation